Developments in gene delivery vectors for ocular gene therapy;La conception de vecteurs adaptés à la thérapie génique oculaire

Medecine/Sciences

Volumn 31, Issue 5, 2015, Pages 529-537

  Khabou, Hanen ^a,b,c   Dalkara, Deniz ^a,b,c  

^a INSTITUT DE LA VISION   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; LENTIVIRUS;

VIRUS DNA; VIRUS RECEPTOR; VIRUS RNA;

ADENOVIRIDAE; ADMINISTRATION AND DOSAGE; ANIMAL; DEPENDOPARVOVIRUS; DIRECTED MOLECULAR EVOLUTION; EYE DISEASES; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; LENTIVIRINAE; MOUSE; PHYSIOLOGY; PRIMATE; RETINA; SITE DIRECTED MUTAGENESIS; THERAPEUTIC USE; TRANSGENE; TRANSLATIONAL RESEARCH; ULTRASTRUCTURE; VIRAL TROPISM; VIRUS CAPSID;

ADENOVIRIDAE; ANIMALS; CAPSID; DEPENDOVIRUS; DIRECTED MOLECULAR EVOLUTION; DNA, VIRAL; EYE DISEASES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAOCULAR; LENTIVIRUS; MICE; MUTAGENESIS, INSERTIONAL; MUTAGENESIS, SITE-DIRECTED; PRIMATES; RECEPTORS, VIRUS; RETINA; RNA, VIRAL; TRANSDUCTION, GENETIC; TRANSGENES; TRANSLATIONAL MEDICAL RESEARCH; VIRAL TROPISM;

EID: 84931049463     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/20153105015     Document Type: Review

References (50)

1. Wright AF, Chakarova CF, Abd El-Aziz MM, Bhattacharya SS. Photoreceptor degeneration: genetic and mechanistic dissection of a complex trait. Nat Rev Genet 2010; 11 : 273-84.
2. Bainbridge JWB, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358 : 2231-9.
3. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA 2008; 105 : 15112-7.
4. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358 : 2240-8.
5. Maclaren RE, Groppe M, Barnard AR, et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 2014; 383 : 1129-37.
6. Bainbridge JW, Ali RR. Success in sight: the eyes have it! Ocular gene therapy trials for LCA look promising. Gene Ther 2008; 15 : 1191-2.
7. Koirala A, Conley SM, Naash MI. A review of therapeutic prospects of nonviral gene therapy in the retinal pigment epithelium. Biomaterials 2013; 34 : 7158-67.
8. Vandenberghe LH, Auricchio A. Novel adeno-associated viral vectors for retinal gene therapy. Gene Ther 2012; 19 : 162-8.
9. Han Z, Conley SM, Naash MI. AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects. Invest Ophthalmol Vis Sci 2011; 52 : 3051-9.
10. Bennett J, Wilson J, Sun D, et al. Adenovirus vector-mediated in vivo gene transfer into adult murine retina. Invest Ophthalmol Vis Sci 1994; 35 : 2535-42.
11. Reichel MB, Ali RR, Thrasher AJ, et al. Immune responses limit adenovirally mediated gene expression in the adult mouse eye. Gene Ther 1998; 5 : 1038-46.
12. Vollrath D, Feng W, Duncan JL, et al. Correction of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk. Proc Natl Acad Sci USA 2001; 98 : 12584-89.
13. Burcin MM, Schiedner G, Kochanek S, et al. Adenovirus-mediated regulable target gene expression in vivo. Proc Natl Acad Sci USA 1999; 96 : 355-60.
14. Balaggan KS, Ali RR. Ocular gene delivery using lentiviral vectors. Gene Ther 2012; 19 : 145-53.
15. Duisit G, Conrath H, Saleun S, et al. Five recombinant simian immunodeficiency virus pseudotypes lead to exclusive transduction of retinal pigmented epithelium in rat. Mol Ther 2002; 6 : 446-54.
16. Kachi S, Binley K, Yokoi K, et al. Equine infectious anemia viral vectormediated codelivery of endostatin and angiostatin driven by retinal pigmented epithelium-specific VMD2 promoter inhibits choroidal neovascularization. Hum Gene Ther 2009; 20 : 31-9.
17. Bemelmans AP, Kostic C, Crippa SV, et al. Lentiviral gene transfer of Rpe65 rescues survival and function of cones in a mouse model of leber congenital amaurosis. PLoS Med 2006; 3 : 1892-903.
18. Balaggan KS, Binley K, Esapa M, et al. Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors. J Gene Med 2006; 8 : 275-85.
19. Lipinski D, Barnard A. Venezuelan equine encephalitis virus-derived glycoprotein-pseudotyped lentivirus vectors differentially transduce corneal endothelium, trabecular meshwork. Hum Gene Ther 2013; 25 : 50-62.
20. Binley K, Widdowson P, Loader J, et al. Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: safety and biodistribution of StarGen for Stargardt disease. Invest Ophthalmol Vis Sci 2013; 54 : 4061-71.
21. Hellström M, Ruitenberg MJ, Pollett MA, et al. Cellular tropism and transduction properties of seven adeno-associated viral vector serotypes in adult retina after intravitreal injection. Gene Ther 2009; 16 : 521-32.
22. Allocca M, Mussolino C, Garcia-Hoyos M, et al. Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. J Virol 2007; 81 : 11372-80.
23. Nathwani AC, Tuddenham EGD, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365 : 2357-65.
24. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24 : 257-61.
25. Büning H, Perabo L, Coutelle O, et al. Recent developments in adeno-associated virus vector technology. J Gene Med 2008; 10 : 717-33.
26. Nonnenmacher M, Weber T. Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther 2012; 19 : 649-58.
27. Abraham D, Handler C, Dashwood M, Coghlan G. Advances in vascular medicine. Google eBook : Springer, 2010. http://books.google.com/books?id=EYp-Wa6CKtkC&pgis=1
28. Nonnenmacher M, Weber T. Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther 2012; 19 : 649-58.
29. Zhong L, Li B, Mah CS, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 2008; 105 : 7827-32.
30. Kay CN, Ryals RC, Aslanidi GV, et al. Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. PLoS One 2013; 8 : e62097.
31. Petrs-Silva H, Dinculescu A, Li Q, et al. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19 : 293-301.
32. Dalkara D, Byrne LLC, Klimczak RR, et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med 2013 ; 5 :189ra76.
33. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 2006; 24 : 198-204.
34. Müller OJ, Kaul F, Weitzman MD, et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 2003; 21 : 1040-6.
35. Klimczak RR, Koerber JT, Dalkara D, et al. A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Müller cells. PLoS One 2009; 4 : e7467.
36. Dalkara D, Kolstad KD, Guerin KI, et al. AAV mediated GDNF secretion from retinal glia slows down retinal degeneration in a rat model of retinitis pigmentosa. Mol Ther 2011; 19 : 1602-8.
37. Yin L, Greenberg K, Hunter JJ, et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52 : 2775-83.
38. Dalkara D, Kolstad KD, Caporale N, et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther 2009; 17 : 2096-102.
39. Petrs-Silva H, Dinculescu A, Li Q, et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 2009; 17 : 463-71.
40. Doroudchi MM, Greenberg KP, Liu J, et al. Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness. Mol Ther 2011; 19 : 1220-9.
41. Dorrell MI, Aguilar E, Jacobson R, et al. Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularizationassociated oxidative stress. J Clin Invest 2009; 119 : 611-23.
42. Koerber JT, Klimczak R, Jang JH, et al. Molecular evolution of adenoassociated virus for enhanced glial gene delivery. Mol Ther 2009; 17 : 2088-95.
43. Auricchio A, Kobinger G, Anand V, et al. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet 2001; 10 : 3075-81.
44. Petrs-Silva H, Dinculescu A, Li Q, et al. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2009; 19 : 293-301.
45. Natkunarajah M, Trittibach P, McIntosh J, et al. Assessment of ocular transduction using single-stranded and self-complementary recombinant adeno-associated virus serotype 2/8. Gene Ther 2008; 15 : 463-7.
46. Weber M, Rabinowitz J, Provost N, et al. Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery. Mol Ther 2003; 7 : 774-81.
47. Allocca M, Doria M, Petrillo M, et al. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest 2008; 118 : 1955-64.
48. Bennett J, Maguire AM, Cideciyan AV, et al. Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina. Proc Natl Acad Sci USA 1999; 96 : 9920-5.
49. Vandenberghe LH, Bell P, Maguire AM, et al. AAV9 targets cone photoreceptors in the nonhuman primate retina. PLoS One 2013; 8 : e53463.
50. Yin L, Greenberg K, Hunter JJ, et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52 : 2775-83.